-
Mashup Score: 0Case Discussions in Recurrent C difficile Management: New Horizons in Microbiome Therapies - 10 month(s) ago
Live biotherapeutic products for prevention of Clostridioides difficile recurrence are now approved. Are you ready?
Source: MedscapeCategories: Latest Headlines, PediatricsTweet
-
Mashup Score: 0Case Discussions in Recurrent C difficile Management: New Horizons in Microbiome Therapies - 10 month(s) ago
Live biotherapeutic products for prevention of Clostridioides difficile recurrence are now approved. Are you ready?
Source: MedscapeCategories: Latest Headlines, PediatricsTweet-
❗ Our latest educational program is here to help you gain a deeper understanding of the microbiome-targeted therapies to reduce the risk of recurrent C difficile infection. #Cdifficile #MedEd #pediatrician https://t.co/OIGQgQQcoX
-
-
Mashup Score: 0Case Discussions in Recurrent C difficile Management: New Horizons in Microbiome Therapies - 10 month(s) ago
Live biotherapeutic products for prevention of Clostridioides difficile recurrence are now approved. Are you ready?
Source: MedscapeCategories: Latest Headlines, PediatricsTweet-
❗ Our latest educational program is here to help you gain a deeper understanding of the microbiome-targeted therapies to reduce the risk of recurrent C difficile infection. #Cdifficile #MedEd #pediatrician https://t.co/k7sttOdHkv
-
-
Mashup Score: 1Changes on horizon may help lessen C. difficile burden - 10 month(s) ago
The COVID-19 pandemic underscored challenges in the prevention and treatment of health care-associated infections.
Source: www.healio.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Changes on horizon may help lessen #Cdifficile burden Jennifer Ross, PharmD https://t.co/OfsPlbraV8 @GoHealio
-
-
Mashup Score: 2
The impact of autocancellation of uncollected Clostridioides difficile specimens after 24 hours on reported healthcare-associated infections: A quality improvement intervention
Source: Cambridge CoreCategories: Infectious Disease, Latest HeadlinesTweet-
New in @ICHEJournal: @Madelin85733066 and colleagues leveraged EHR to reduce non-clinical #Cdifficile HAI - 24 hour "autocancel" of uncollected stool. Learn what happened at 17 hospitals 👇 📄: https://t.co/BgC4cI27ee https://t.co/mABlCTsBhT
-
-
Mashup Score: 1Management of Clostridoides Difficile: A Focus on the Pharmacist's Role in the Care Continuum - 10 month(s) ago
Patient education and counseling play a critical role in preventing C. difficile recurrence, and pharmacists are uniquely positioned to provide treatment recommendations, educate patients and health care providers, optimize transitions of care, and reduce the risk of recurrent CDI.
Source: Pharmacy TimesCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Pharmacists are uniquely positioned to provide treatment recommendations, educate patients and health care providers, optimize transitions of care, and reduce the risk of recurrent CDI. #cdifficile Read More: https://t.co/27h8fwKNT8
-
-
Mashup Score: 0Case Discussions in Recurrent C difficile Management: New Horizons in Microbiome Therapies - 11 month(s) ago
Live biotherapeutic products for prevention of Clostridioides difficile recurrence are now approved. Are you ready?
Source: MedscapeCategories: Latest Headlines, PediatricsTweet-
❗ Our latest educational program is here to help you gain a deeper understanding of the microbiome-targeted therapies to reduce the risk of recurrent C difficile infection. #Cdifficile #MedEd #pediatrician https://t.co/rC9F5bciBk
-
-
Mashup Score: 0Case Discussions in Recurrent C difficile Management: New Horizons in Microbiome Therapies - 11 month(s) ago
Live biotherapeutic products for prevention of Clostridioides difficile recurrence are now approved. Are you ready?
Source: MedscapeCategories: Latest Headlines, PediatricsTweet-
❗ Our latest educational program is here to help you gain a deeper understanding of the microbiome-targeted therapies to reduce the risk of recurrent C difficile infection. #Cdifficile #MedEd #pediatrician https://t.co/tSJkhcR6CN
-
-
Mashup Score: 0VIDEO: Low risk for congestive heart failure exacerbation with Zinplava for C. difficile - 11 month(s) ago
CHICAGO — In this Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, recaps results from a real-world analysis of Zinplava for prevention of recurrent Clostridioides difficile infection in patients with congestive heart failure.“C. difficile is a major problem in the United States,” Feuerstadt, assistant clinical professor of medicine at Yale University School of Medicine
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from #DDW23: Low risk for congestive #heartfailure exacerbation with #Zinplava for #Cdifficile @DDWMeeting https://t.co/YYqm3fVwIx
-
-
Mashup Score: 0Case Discussions in Recurrent C difficile Management: New Horizons in Microbiome Therapies - 11 month(s) ago
Live biotherapeutic products for prevention of Clostridioides difficile recurrence are now approved. Are you ready?
Source: MedscapeCategories: Latest Headlines, PediatricsTweet-
❗ Our latest educational program is here to help you gain a deeper understanding of the microbiome-targeted therapies to reduce the risk of recurrent C difficile infection. #Cdifficile #MedEd #pediatrician https://t.co/h0TTGxBut6
-
❗ Our latest educational program is here to help you gain a deeper understanding of the microbiome-targeted therapies to reduce the risk of recurrent C difficile infection. #Cdifficile #MedEd #pediatrician https://t.co/798ze8xdOH